Chronic thrombotic microangiopathy presenting as acute nephrotic syndrome in a patient with renal cancer receiving tyrosine kinase inhibitor therapy
Authors:
Open Access
- 5 January 2024
- journal article
- research article
- Published by BMJ in BMJ Case Reports
- Vol. 17 (1) , e255841
Abstract
Thrombotic microangiopathy (TMA) is a rare but serious side effect of tyrosine kinase inhibitor (TKI) therapy. Previous case reports of renal TMA have usually occurred in the first few months of TKI initiation with only very few cases occurring within 2–3 years. We report a case of a patient who was referred to the Nephrology service for nephrotic syndrome and worsening renal function after 8 years of sunitinib therapy for metastatic clear cell carcinoma of the kidney. Renal biopsy showed chronic TMA without another secondary aetiology identified. With discontinuation of sunitinib and pharmacological optimisation of his hypertension, his renal function and proteinuria both significantly improved. No relapse or recurrence of disease activity was noted after a year of follow-up. This case highlights the importance of remaining vigilant for the development of renal TMA even after an extended duration of TKI therapy.Keywords
This publication has 45 references indexed in Scilit:
- Sunitinib induced nephrotic syndrome and thrombotic microangiopathyIndian Journal of Nephrology, 2013
- Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with SunitinibCase Reports in Oncology, 2012
- Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathyNephrology Dialysis Transplantation, 2009
- Nephrotic Syndrome and Acute Renal Failure Apparently Induced by SunitinibCase Reports in Oncology, 2009
- Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinibNephrology Dialysis Transplantation, 2008
- Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteriaNephrology Dialysis Transplantation, 2008
- VEGF Inhibition and Renal Thrombotic MicroangiopathyNew England Journal of Medicine, 2008
- TTP-HUS Associated with SunitinibCancer Research and Treatment, 2008
- Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitorBiochemical and Biophysical Research Communications, 2007
- Thrombotic microangiopathy and anti-VEGF agentsNephrology Dialysis Transplantation, 2007